SNY

2 Stocks to Buy, 2 to Sell in Big Pharma

Big Pharma's on a roll these days along with the larger healthcare sector. With that in mind, here are two stocks to buy and two to sell in leading industries. More 

New Asthma Drug Could Be Game Changer

An asthma drug developed by Sanofi and Regeneron reduced asthma attacks by 87% in a mid-stage drug trial. More 

Bulls vs. Bears: Can Biogen Keep Booming?

Biogen has been soaring on news of its recent drug approval, but the question remains when it can keep it up. Here are the bullish and bearish arguments. More 

Intimidated By Your New 401k? Try a Target-Date Fund

Signing up for a 401k is cake, but deciding how to allocate your funds isn't so easy. Target-date mutual funds can shoulder that burden. More 

The Best and Worst Mutual Funds of Q1 2013

Healthcare and Japanese stocks were among some of the hottest mutual fund flavors of the year's first quarter, while India and gold lagged behind. More 

FDA Approves New Biogen Drug to Treat MS

The Food and Drug Administration has approved Biogen Idec's new multiple sclerosis capsule, Tecfidera. More 

Winners After Novo Nordisk’s Insulin Rejection

Eli Lilly and Sanofi look like the biggest players that are best suited to benefit from Novo Nordisk's diabetes-drug setback, but a smaller player could emerge, too. More